247 related articles for article (PubMed ID: 35330059)
1. PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers.
Teyssonneau D; Thiery-Vuillemin A; Dariane C; Barret E; Beauval JB; Brureau L; Créhange G; Fiard G; Fromont G; Gauthé M; Ruffion A; Renard-Penna R; Mathieu R; Sargos P; Rouprêt M; Ploussard G; Roubaud G; On Behalf Of The Cc-Afu Cancerology Committee Of The Association Française d'Urologie
J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35330059
[TBL] [Abstract][Full Text] [Related]
2. PARP inhibitors in prostate cancers, is it time for combinations?
Teyssonneau D; Dariane C; Barret E; Beauval JB; Brureau L; Fiard G; Fromont G; Créhange G; Gauthé M; Ruffion A; Renard-Penna R; Mathieu R; Sargos P; Rouprêt M; Ploussard G; Roubaud G
Ther Adv Med Oncol; 2024; 16():17588359241242959. PubMed ID: 38827177
[TBL] [Abstract][Full Text] [Related]
3. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
4. Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer.
Inderjeeth AJ; Topp M; Sanij E; Castro E; Sandhu S
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497408
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
Jang A; Sartor O; Barata PC; Paller CJ
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33233320
[TBL] [Abstract][Full Text] [Related]
6. Development of PARP inhibitors in advanced prostate cancer.
Bourlon MT; Valdez P; Castro E
Ther Adv Med Oncol; 2024; 16():17588359231221337. PubMed ID: 38205078
[TBL] [Abstract][Full Text] [Related]
7. Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer.
Maughan BL; Antonarakis ES
Expert Opin Pharmacother; 2021 Aug; 22(12):1625-1632. PubMed ID: 33827356
[TBL] [Abstract][Full Text] [Related]
8. PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence.
Bieńkowski M; Tomasik B; Braun M; Jassem J
Cancer Treat Rev; 2022 Mar; 104():102359. PubMed ID: 35190335
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer and PARP inhibitors: progress and challenges.
Teyssonneau D; Margot H; Cabart M; Anonnay M; Sargos P; Vuong NS; Soubeyran I; Sevenet N; Roubaud G
J Hematol Oncol; 2021 Mar; 14(1):51. PubMed ID: 33781305
[TBL] [Abstract][Full Text] [Related]
10. PARP inhibitors in metastatic prostate cancer.
Taylor AK; Kosoff D; Emamekhoo H; Lang JM; Kyriakopoulos CE
Front Oncol; 2023; 13():1159557. PubMed ID: 37168382
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of PARP inhibitors in prostate cancer.
Stellato M; Guadalupi V; Sepe P; Mennitto A; Claps M; Zattarin E; Verzoni E; Valdagni R; De Braud FG; Santini D; Tonini G; Procopio G
Expert Rev Anticancer Ther; 2020 Aug; 20(8):715-726. PubMed ID: 32758032
[TBL] [Abstract][Full Text] [Related]
12. PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures.
McNevin CS; Cadoo K; Baird AM; Finn SP; McDermott R
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230674
[TBL] [Abstract][Full Text] [Related]
13. PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic Landscape.
Al-Akhras A; Hage Chehade C; Narang A; Swami U
Life (Basel); 2024 Jan; 14(2):. PubMed ID: 38398706
[TBL] [Abstract][Full Text] [Related]
14. Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology.
Ziadeh T; Kourie HR
Pharmacogenomics; 2021 Dec; 22(18):1237-1250. PubMed ID: 34729995
[TBL] [Abstract][Full Text] [Related]
15. Olaparib for the treatment of metastatic prostate cancer.
Dror CM; Wyatt AW; Chi KN
Future Oncol; 2021 Jul; 17(19):2413-2429. PubMed ID: 33769071
[TBL] [Abstract][Full Text] [Related]
16. Poly (ADP-ribose) polymerase inhibitors (PARPi) for advanced malignancies with multiple DNA-repair genetic aberrations.
Hu J; Liang P; Jin D; Fan R; Xie X; Liu C; Jiang Q; Gao L
Expert Rev Anticancer Ther; 2022 Jul; 22(7):717-723. PubMed ID: 35679134
[TBL] [Abstract][Full Text] [Related]
17. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
18. Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.
Schettini F; Giudici F; Bernocchi O; Sirico M; Corona SP; Giuliano M; Locci M; Paris I; Scambia G; De Placido S; Rescigno P; Prat A; Curigliano G; Generali D
Eur J Cancer; 2021 May; 149():134-152. PubMed ID: 33862496
[TBL] [Abstract][Full Text] [Related]
19. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
20. PARP Inhibitors in the Treatment of Prostate Cancer: From Scientific Rationale to Clinical Development.
Kwon WA
World J Mens Health; 2024 Apr; 42(2):290-303. PubMed ID: 37853532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
